Taj Pharma supplies Deferasirox dispersible tablets under the buyer's own registered trademark - a private-label or contract-manufacturing arrangement that combines our manufacturing, quality and regulatory capabilities with your brand equity in the destination market.
Service Scope #
- Manufacture of Deferasirox dispersible tablets to the DEFRATAJ specification, packaged under buyer's brand name and artwork
- Multilingual leaflet and carton preparation
- Country-specific GTIN and serialisation coding where required
- Custom blister cavity counts, HDPE bottle presentations, or co-packed formats
- Full CTD dossier support for buyer-led registration
- Post-approval variation and lifecycle management
Brand Ownership & IP #
The buyer retains full ownership of its trademark. Taj Pharma holds the manufacturing process IP and ICH Q8/Q9/Q10 lifecycle documentation. A Manufacturing and Supply Agreement defines brand use, exclusivity (where granted), territory, minimum-order commitments and term.
Typical Customer Profiles #
- Established in-market distributor with existing portfolio under own brand
- Regional wholesaler launching a branded-generic line
- Hospital group seeking a consistent, audited supply under a custom identifier
- NGO / donor programme requiring neutral-branded supply for public-sector distribution
Artwork & Language Capability #
| Element | Customisation |
|---|---|
| Carton | Buyer brand logo, color, regulatory overprint |
| Blister foil | Buyer name, generic, batch / expiry overprint |
| Leaflet | Buyer-approved patient information in target language(s) - EN / FR / PT / ES / AR supported |
| GTIN / barcode | Buyer-owned GTIN; GS1 DataMatrix where required |
Regulatory Support #
Private-label launches are supported with a full CTD dossier in buyer's name (or in Taj Pharma's name with MAH transfer clause), stability data appropriate to the market climatic zone, and change-control for post-approval variations.
Minimum Commitments #
Private-label programmes typically carry a minimum order quantity (MOQ) per SKU and a minimum annual take to justify dedicated artwork and regulatory investment. Indicative terms are shared on signing of a CDA.